Trimetazidine did not provide cardiac support in wild-type ATTR-CM
Trimetazidine did not improve heart function or exercise capacity in patients with wild-type transthyretin cardiac amyloidosis.
News
-
-
Most patients with ATTR-CM are in advanced stages despite recent diagnosis: study
Despite relatively recent diagnosis (four months), most patients had advanced transthyretin amyloid cardiomyopathy (ATTR-CM).
-
Ventilation abnormalities are key in ATTR-CM exercise limitation, study says
Ventilation abnormalities appeared to play a more important role in ATTR-CM-associated shortness of breath than cardiac output abnormalities.
-
FDA evaluates supplemental application for vutrisiran to treat patients with ATTR-CM
If approved, vutrisiran would become the first U.S. treatment to treat both polyneuropathy and cardiomyopathy linked to ATTR.
-
Tafamidis shows long-term benefits in slowing ATTR-CM progression
Nine years of treatment with tafamidis prevented hospitalizations for heart failure in two patients with ATTR-CM.
-
ATTR-CM is more frequent in women than previously believed: study
ATTR-CM is thought to affect mainly men. But recent studies suggest that more women could have the disease than earlier thought.
-
Study offers a snapshot of patients with ATTR-CM in Australia and New Zealand
A study detailed the characteristics of people with the disease in ATTR-CM centers in the two Australasian countries.
-
Study suggests ATTR-CM can be detected before symptom onset
A systematic screening process for relatives of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) has shown promising results.
-
Tafamidis reduced amyloid in ATTR-CM but showed no symptom improvement
The study results suggested that tafamidis may stabilize ATTR-CM progression rather than reverse its effects.
-
Single dose of ATTR therapy nucresiran reduced TTR levels, company says
Nucresiran showed potential as a treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM), Alnylam Pharmaceuticals said.